Reply to: Therapeutic Drug Monitoring for IBD Children on Thioguanine
- PMID: 37346010
- DOI: 10.1097/MPG.0000000000003871
Reply to: Therapeutic Drug Monitoring for IBD Children on Thioguanine
Comment on
-
Safety of Thioguanine in Pediatric Inflammatory Bowel Disease: A Multi-Center Case Series.J Pediatr Gastroenterol Nutr. 2022 Dec 1;75(6):e111-e115. doi: 10.1097/MPG.0000000000003621. Epub 2022 Sep 20. J Pediatr Gastroenterol Nutr. 2022. PMID: 36136124 Free PMC article.
-
Therapeutic Drug Monitoring for IBD Children on Thioguanine.J Pediatr Gastroenterol Nutr. 2023 Sep 1;77(3):e64-e65. doi: 10.1097/MPG.0000000000003870. Epub 2023 Jun 22. J Pediatr Gastroenterol Nutr. 2023. PMID: 37346029 No abstract available.
References
-
- Bayoumy AB, Jagt JZ, van Wering HM, et al. Safety of thioguanine in pediatric inflammatory bowel disease: a multi-center case series. J Pediatr Gastroenterol Nutr 2022;75:e111–5.
-
- Florin TH, Duley JA. Therapeutic drug monitoring for IBD children on thioguanine. J Pediatr Gastroenterol Nutr 2023; Epub ahead of print.
-
- De Boer N, Wilhelm A, van Bodegraven A, et al. Guideline therapeutic drug monitoring thiopurines. 2018. https://tdm-monografie.org/monografie/thiopurines . Accessed February 10, 2023.
-
- Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003;125:298–303.
-
- Derijks LJ, de Jong DJ, Gilissen LP, et al. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 2003;15:63–7.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
